187 Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Jalid Sehouli,Ignace Vergote,Erika Hamilton,Alejandro Pérez Fidalgo,Toon Van Gorp,Giovanni Scambia,Jaroslav Klat,Tally Levy,Stephen Welch,Debra L Richardson,Eva Maria Guerra Alía,Stéphanie Henry,Pauline Wimberger,David S Miller,Jerónimo Martínez,Bradley J Monk,Pratheek Kalyanapu,Monsoor Raza Mirza,Vicky Makker

doi:10.1136/ijgc-2024-esgo.20

187 Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Jalid Sehouli, Ignace Vergote + Show 17 more

https://doi.org/10.1136/ijgc-2024-esgo.20

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society	Publication Date: Mar 1, 2024
Citations: 1

Affiliation: Wolfson Medical Center, University Hospital Carl Gustav Carus, Hospital Universitario Virgen de la Arrixaca, Gynecologic Oncology Group, Copenhagen University Hospital, Memorial Sloan Kettering Cancer Center

#Clovis Oncology #Karyopharm Therapeutics + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

187 Selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: long-term follow up of efficacy and safety subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study

Full Text